Melis Anahtar is a co-founder of Day Zero Diagnostics. After a biomedical engineering degree at MIT, she studied immunology on a Rhodes Scholarship in Oxford and in the Harvard MD-PhD Program. She then had a Residency and Medical Microbiology fellowship at MGH.

James J. Collins is Termeer Professor of Bioengineering in the Department of Biological Engineering and Institute for Medical Engineering & Science. He is also affiliated with the Broad Institute and the Wyss Institute. His research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance. Professor Collins' patented technologies have been licensed by over 25 biotech, pharma and medical devices companies, and he has helped to launched a number of companies, including Sample6 Technologies, Synlogic and EnBiotix.

Daniel Goodwin a technologist in love with the brain. After several years in Silicon Valley, he is working towards his PhD at the MIT Media Lab under Professor Ed Boyden. The lab, The Synthetic Neurobiology Group, seeks to lead the world's mission to "solve the brain" by building the next generation of tools for neuroscience.

Mo Khalil is the Dorf-Ebner Distinguished Associate Professor of Biomedical Engineering and Founding Associate Director of the Biological Design Center at Boston University. He is also a Visiting Scholar at the Wyss Institute for Biologically Inspired Engineering at Harvard University, and Co-Director of a NIH/NIGMS T32 PhD Training Program in synthetic biology. He was an HHMI Postdoctoral Fellow with Dr. Jim Collins at BU working in systems & synthetic biology. He completed his PhD at MIT with Drs. Angela Belcher and Matt Lang in molecular biophysics & engineering. Mo is co-founder of K2 Biotechnologies and Fynch Biosciences, serves on the Scientific Advisory Board for Chroma Medicine and Senti Biosciences, and consults for numerous other biotechnology and therapeutics companies.

Cammie Lesser currently is at MGH. The Lesser lab is interested in understanding how bacterial pathogens manipulate host cell processes to promote their own survival and replication during the course of an infection.

Debbie Marks is a mathematician and computational biologist with a track record of using novel algorithms and statistics to successfully address unsolved biological problems. She has a passion for interpreting genetic variation in a way that impacts biomedical applications. During her PhD, she quantified the potential pan-genomic scope of microRNA targeting and combinatorial regulation of protein expression and co-discovered the first microRNA in a virus. As a postdoc she and her colleagues cracked the classic, unsolved problem of ab initio 3D structure prediction of proteins using a maximum entropy probability model for evolutionary sequences.

Shannon Nangle is the founder of Circe. She believes industrial biotech is a necessary part of our collective solutions to climate change and that its expansion lies in the development of inexpensive and sustainable feedstocks, specifically carbon dioxide.

Analise Reeves is an experienced molecular geneticist and synthetic biologist, whose career has focused on developing and engineering biologics based therapeutics. As the current Head of Synthetic Biology Operations at a mid-sized biotechnology company, she coordinates projects across teams from the early discovery stage through entry into Phase 1 clinical trails. Her hope as a Scientific Advisor for WISH is to create new opportunities for deserving young scientists that lead to exciting future insights and innovations, and to pay forward the invaluable support and mentorship she received during her own education.

Dan Robinson is the Climate Initiative Lead at Ginkgo Bioworks where he is building out Ginkgo Bioworks' activities across carbon dioxide removal (CDR) and C1 biomanufacturing -- commercial deals, ecosystem partners, and company creation on the Ginkgo platform.

Sam Sinai is a computational biologist with expertise in evolution and machine learning. He received his PhD under George Church and Martin Nowak at Harvard, where he used mathematics and machine learning to develop models of biological systems. In particular, he developed the underpinnings of Dyno's machine learning strategy in collaboration with Eric, and has co-authored multiple papers on the subject. He previously obtained his B.S. and M.Eng. in computer Science at MIT with a focus on A.l., and had a brief stint in medical school.

Chris Voigt obtained his Bachelor’s degree in Chemical Engineering at the University of Michigan, Ann Arbor and a PhD in Biochemistry and Biophysics at the California Institute of Technology. He continued his postdoctoral research in Bioengineering at the University of California, Berkeley. His academic career commenced as an Assistant and Associate Professor at the Department of Pharmaceutical Chemistry at the University of California-San Francisco. Chris Voigt joined the Department of Biological Engineering at MIT as Associate Professor in 2011.

Ron Weiss is one of the pioneers of synthetic biology. He has been engaged in synthetic biology research since 1996 when he was a graduate student at MIT and where he helped set up a wet-lab in the Electrical Engineering and Computer Science Department. After completion of his PhD, Weiss joined the faculty at Princeton University, and recently returned to MIT to take on a tenured faculty position in the Department of Biological Engineering and the Department of Electrical Engineering and Computer Science.

Ben Woolston joined the NEU Chemical Engineering department as an Assistant Professor in January 2020. At Northeastern, his research program combines approaches from his previous research training in metabolic engineering, synthetic biology, biochemistry and microbiology to engineer microbes for biofuel & biochemical production, and as diagnostics and therapeutics in the human gut microbiota.